Prime Medicine Inc (PRME)
5.79
+0.43
(+8.02%)
USD |
NASDAQ |
May 09, 15:44
Prime Medicine EPS Diluted (Quarterly): -0.72 for Dec. 31, 2023
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.72 |
| September 30, 2023 | -0.55 |
| June 30, 2023 | -0.47 |
| March 31, 2023 | -0.44 |
| December 31, 2022 | -0.56 |
| September 30, 2022 | -0.3786 |
| Date | Value |
|---|---|
| June 30, 2022 | -0.4964 |
| March 31, 2022 | -0.4187 |
| December 31, 2021 | -0.9649 |
| September 30, 2021 | -0.3172 |
| December 31, 2019 | -0.039 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.9649
Minimum
Dec 2021
-0.039
Maximum
Dec 2019
-0.4868
Average
-0.47
Median
Jun 2023
EPS Diluted (Quarterly) Benchmarks
| 10x Genomics Inc | -0.50 |
| Verve Therapeutics Inc | -0.69 |
| Ionis Pharmaceuticals Inc | -0.98 |
| Solid Biosciences Inc | -1.00 |
| Beam Therapeutics Inc | -1.21 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -65.64M |
| Total Expenses (Quarterly) | 54.54M |
| Enterprise Value | 521.69M |
| Earnings Yield | -37.65% |